BDX vs STRO
Becton Dickinson and Company (BDX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. STRO currently screens at market cap $470.8M.
Not investment advice. Open the BDX and STRO stock pages for the full models.
Not investment advice.